Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders

Absolute Bioavailability of Tasimelteon

(2015) Rosarelis Torres et al.   AMERICAN JOURNAL OF THERAPEUTICS

Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015

(2015) R. Robert Auger et al.   Journal of Clinical Sleep Medicine

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

(2015) Steven W Lockley et al.   LANCET

Tasimelteon: A selective and unique receptor binding profile

(2015) Christian Lavedan et al.   NEUROPHARMACOLOGY

The Melatonin Receptor Agonist Is Effective for Free-Running Type Circadian Rhythm Sleep Disorder: Case Report on Two Sighted Patients

(2014) Mariko Yanagihara et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Challenging behaviour and sleep cycle disorder following brain injury: A preliminary response to agomelatine treatment

(2013) B. O’Neill et al.   BRAIN INJURY

Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel

(2010) Phyllis C. Zee et al.   SLEEP MEDICINE

Ramelteon: a review of its therapeutic potential in sleep disorders

(2009) Seithikurippu R. Pandi-Perumal et al.   ADVANCES IN THERAPY

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials

(2008) Shantha MW Rajaratnam et al.   LANCET

A three pulse phase response curve to three milligrams of melatonin in humans

(2007) Helen J. Burgess et al.   JOURNAL OF PHYSIOLOGY-LONDON